Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD

Brief summary (registry, in English)

The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease. The main question it aims to answer is: Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)? Researchers will compare the 'first-time-right' strategy group to the current practice group to see if there are improvements in major adverse cardiac and cerebrovascular events (MACE) at 36 months. Participants will: * Receive either the 'first-time-right' strategy or current practice for secondary prevention. * Be monitored (data collection) through routine clinical visits at baseline, 8 weeks, 12, and additional telephone contacts at 24, and 36 months after discharge. * Complete online questionnaires at hospitalization, 8 weeks, 12, 24, and 36 months after discharge.

What you commit to

• Study type: Observational
• Planned participants: 5586
• From 9 Jul 2024 to the primary completion date, Jan 2029
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.